Blood Reviews
Volume 17, Issue 3 , Pages 131-142 , September 2003

Primary cutaneous lymphomas: a review with current treatment options

  • Christiane Querfeld

      Affiliations

    • Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    • ,
  • Joan Guitart

      Affiliations

    • Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    • ,
  • Timothy M. Kuzel

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    • ,
  • Steven T. Rosen

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    • Corresponding Author InformationCorrespondence to: Steven T. Rosen, Department of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 710 N Fairbanks Court-Oslen 8250 Chicago, Illinois, USA. Tel.: +1-312-908-5250; Fax: +1-312-908-1372

References 

  1. Liang X, Smoller BR, Golitz LE. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders. J. Cutan. Pathol. 2002;29:459–464
  2. Drillenburg P, Pals T. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900–1910
  3. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88:3259–3287
  4. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function and association with the malignant process. Adv. Cancer Res. 1997;71:241–319
  5. Burg G, Kempf W, Haeffner AC, et al.  Cutaneous lymphomas. Curr. Probl. Dermatol. 1997;9:137–204
  6. Wood GS. T-cell receptor and immunoglobulin gene rearrangements in diagnosing skin disease. Arch. Dermatol. 2001;137:1503–1506
  7. Willemze R, Kerl H, Sterry W, et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
  8. Fink-Puches R, Zenahlik P, Bäck B, et al.  Primary cutaneous lymphomas: applicability of current classification schemes (European Organisation for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2000;99:800–805
  9. Knobler R, Burg G, Whittaker S, et al.  EORTC cutaneous lymphoma task force. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer. 2002;38(Suppl 4):S60–64
  10. Akdis M, Klunker S, Schliz M, et al.  Expression of cutaneous lymphocyte-associated antigen on human CD4+ and CD8+ Th2 cells. Eur. J. Immunol. 2000;30:3533–3541
  11. Lee BN, Duvic M, Tang CK, et al.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T-cells of patients with cutaneous T-cell lymphoma. Clin. Diagn. Lab. Immunol. 1999;6:79–84
  12. Boulland ML, Meignin V, Leroy-Viard K, et al.  Human interleukin-10 expression in T/natural killer-cell lymphoma. Am. J. Pathol. 1998;153:1229–1237
  13. Vowels BR, Lessin SR, Cassin M, et al.  Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J. Invest. Dermatol. 1994;103:669–673
  14. Rook AH, Vowels BR, Jaworsky C, et al.  The immunopathogenesis of cutaneous T-cell lymphoma. Arch. Dermatol. 1993;123:757–763
  15. van Doorn R, Dijkman R, Vermeer M, et al.  A novel splice variant of the FAS gene in patients with cutaneous T-cell lymphoma. Cancer Res. 2002;62:5389–5392
  16. Kempf W, Levi E, Kamarashev J, et al.  Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J. Cutan. Pathol. 2002;29:295–300
  17. Zoi-Toli O, Vermeer MH, De Vries E, et al.  Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of FAS expression and aggressive types of CTCL. Brit. J. Dermatol. 2000;143:313–319
  18. Mao X, Orchard G, Lillington D, et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2002;8:2434
  19. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J. Am. Acad. Dermatol. 2002;46:325–357
  20. Zackheim HS, Vonderheid EC, Ramsay DL, et al.  Relative frequency of various forms of primary cutaneous lymphomas. J. Am. Acad. Dermatol. 2000;43:793–796
  21. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am. J. Public Health. 1999;89:1240–1244
  22. Akaraphanth R, Douglass MC, Lim HW. Hypopigmented mycosis fungoides: treatment and a 6(1/2)-year follow-up of 9 patients. J. Am. Acad. Dermatol. 2000;42:33–39
  23. Chen HH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br. J. Dermatol. 2002;147:587–591
  24. Siegel RS, Pandolfino T, Guitart J, et al.  Primary cutaneous T-cell lymphoma: review and current concepts. J. Clin. Oncol. 2000;18:2908–2925
  25. Goerdt S, Trautmann C, Kütting B, et al.  Rare variants of cutaneous T-cell lymphomas. Hautarzt. 1996;47:96–105
  26. Grange F, Bagot M. Prognosis of primary cutaneous lymphomas. Ann. Dermatol. Venerol. 2002;129:30–40
  27. Toro JR, Stoll HL, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J. Am. Acad. Dermatol. 1997;37:58–67
  28. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and Sézary syndrome. Arch. Dermatol. 1995;131:1003–1008
  29. Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 1995;9:943–960
  30. Garzon MC. Cutaneous T cell lymphoma in children. Semin. Cutan. Med. Surg. 1999;18:226–232
  31. Alibert JLM. Tableau de plan fongoide: description des maladies de la peau observeé à l’hôpital St. Louis, et exposition des melleurs methods suivies pour leur trâitement. Paris, France, Barrois l’Aine et Files, 1806
  32. Bazin PAE. Maladies de la peau observeé à l’hôpital St. Louis, Paris, France, 1876
  33. Telle H, Koeppel MC, Jreissati M, et al.  Granulomatous mycosis fungoides. Eur. J. Dermatol. 1998;8:506–510
  34. Guitart J, Peduto M, Caro W, Roenigk HH. Lichenoid changes in mycosis fungoides. J. Am. Acad. Dermatol. 1997;36:417–422
  35. Camisa C, Aulisio A. Pustular mycosis fungoides. Cutis. 1994;54:202–204
  36. LeBoit PE. Variants of mycosis fungoides and related cutaneous T-cell lymphomas. Semin. Diagn. Pathol. 1991;8:73–81
  37. Van Doorn R, Scheffer E, Willemze R, et al.  Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch. Dermatol. 2002;138:191–198
  38. O’Quinn RP, Zic J, Boyd A. Mycosis fungoides d’embleé: CD30-negative cutaneous large T-cell lymphoma. J. Am. Acad. Dermatol. 2000;43:861–863
  39. Vidal E, Brocq L. Étude sur le mycosis fongoide. Le France Medical. 1885;2:949–1085
  40. Haghighi B, Smoller B, LeBoit P, et al.  Pagetoid reticulosis (Woringer–Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod. Pathol. 2000;13:502–510
  41. Nakada T, Sueki H, Ijima N. Disseminated pagetoid reticulosis (Ketron–Goodman disease): six-year follow-up. J. Am. Acad. Dermatol. 2002;47(Suppl 2):S183–S186
  42. Tuyp E, Burgoyne A, Itchison T, et al.  A case control study of possible causative factors in mycosis fungoides. Arch. Dermatol. 1987;123:196–200
  43. Hall WW, Liu CR, Schneewind , et al.  Deleted HTLV-1 provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science. 1991;253:317–320
  44. Zucker-Franklin D, Pancake BA. The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas. Semin. Dermatol. 1994;13:160–165
  45. Wood GS, Schaffer JM, Boni R, et al.  No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma. Am. J. Pathol. 1997;150:667–673
  46. Jackow C, Cather J, Hearne V, et al.  Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion. Blood. 1997;89:32–40
  47. Scarabello A, Leinweber B, Ardigo M, et al.  Cutaneous lymphomas with prominent granulomatous reaction: a potential pitfall in the histopathologic diagnosis of cutaneous T-and B-cell lymphomas. Am. Surg. Pathol. 2002;26:1259–1268
  48. Holm N, Flaig M, Yazdi AS, Sander CA. The value of molecular analysis by PCR in the diagnosis of cutaneous lymphocytic infiltrates. J. Cutan. Pathol. 2002;29:447–452
  49. Li N, Bhawan J. New insights into the applicability of T-cell receptor γ gene rearrangement analysis in cutaneous T-cell lymphoma. J. Cutan. Pathol. 2001;28:412–418
  50. Wood GS. Analysis of clonality in cutaneous T cell lymphoma and associated diseases. Ann. NY Acad. Sci. 2001;941:26–30
  51. Delfaux-Larue MMH, Laroche L, Wechsler J, et al.  Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000;96:2987–2992
  52. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J. Cutan. Pathol. 2002;29:465–472
  53. Berti E, Tomasini D, Vermeer MH, et al.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am. J. Pathol. 1999;155:483–492
  54. Vergier B, de Muret A, Beylot-Barry M, et al.  Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood. 2000;95:2212–2218
  55. El-Shabrawi-Caelen L, Cerroni L, et al.  Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am. J. Surg. Pathol. 2002;26:450–457
  56. Navas IC, Algara P, Mateo M, et al.  p16INK4a is selectively silenced in the tumoral progression of mycosis fungoides. Lab. Invest. 2002;82:123–132
  57. Dereure O, Levi E, Vonderheid E, et al.  Infrequent Fas mutations but no BAX or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J. Invest. Dermatol. 2002;118:949–956
  58. Diamandidou E, Colome M, Fayad L, et al.  Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J. Am. Acad. Dermatol. 1999;40:914–924
  59. Meissner K, Michaelis K, Rehpenning W, Loning T. Epidermal Langerhans cell densities influence survival in mycosis fungoides and sezary syndrome. Cancer. 1990;69:2069–2073
  60. Hoppe RT, Medeiros LJ, Warnke RA, et al.  CD8-positive tumor-infiltrating lymphocytes influence the long-term survival in mycosis fungoides. J. Am. Acad. Dermatol. 1995;32:448–453
  61. Watson A. Photochemotherapy for mycosis fungoides: current status. Australas. J. Dermatol. 1997;38:9–11
  62. Herrmann JJ, Roenigk HH, Hurria A, et al.  Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J. Am. Acad. Dermatol. 1995;33:234–242
  63. Hönigsmann H, Brenner W, Rauschmeier W, et al.  Photochemotherapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1984;10:238–245
  64. Pabsch H, Rötten A, von Stemm A, et al.  Treatment of childhood mycosis fungoides with topical PUVA. J. Am. Acad. Dermatol. 2002;47:557–561
  65. Cochran Gathers R, Scherschun L, Malick F, et al.  Narrowband UVB phototherapy for early-stage mycosis fungoides. J. Am. Acad. Dermatol. 2002;47:191–197
  66. Plettenberg H, Stege H, Megahed M, et al.  Ultraviolet A1 (340–400nm) phototherapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1999;47:191–197
  67. Morita A, Werfel T, Stege H, et al.  Evidence that singlet oxygen-induced human T-helper cell apoptosis is the basic mechanism of ultraviolet—A radiation phototherapy. J. Exp. Med. 1997;186:1763–1768
  68. Bunn PA, Hoffman SJ, Norris D, et al.  Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). Ann. Intern. Med. 1994;121:592–602
  69. Chiarion-Sileni V, Bononi A, Fornasa Veller C, et al.  Phase II trial of interferon-α-2a plus Psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95:569–575
  70. Talpur R, War S, Apisarnthanarax N, et al.  Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2002;47:672–684
  71. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 2002;100:1399–1403
  72. Kuzel TM. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. Clin. Lymphoma. 2000;Suppl 1:S33–S36
  73. Duvic M, Kuzel TM, Olsen EA, et al.  Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (Ontak). Clin. Lymphoma. 2002;2:222–228
  74. Lundin J, Osterborg A, Brittinger G, et al.  CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphoma: a phase II multicenter study. European Study Group of CAMPATH-1H. Treatment in low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol. 1998;16:3257–3263
  75. Guitart J, Wickless SC, Oyama Y, et al.  Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch. Dermatol. 2002;138:1359–1365
  76. Rook AH, Wood GS, Yoo EK. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;902–908
  77. Muche JM, Sterry W. Vaccination therapy for cutaneous T-cell lymphoma. Clin. Exp. Dermatol. 2002;27:602–607
  78. Berger C, Xu AL, Hanlon D, et al.  Induction of human tumor-loaded dendritic cells. Int. J. Cancer. 2001;91:438–447
  79. Zucker-Franklin D. The role of human T cell lymphotropic virus type I tax in the development of cutaneous T cell lymphoma. Ann. NY Acad. Sci. 2001;941:86–96
  80. Dummer R, Nestle FO, Niederer E, et al.  Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7− T lymphocyte subsets in Sézary syndrome. Arch. Dermatol. Res. 1999;291:307–311
  81. Vonderheid EC, Bigler RD, Kotecha A, et al.  Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome). J. Invest. Dermatol. 2001;117:654–662
  82. Vonderheid EC, Bernengo MG, Burg G, et al.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. 2002;46:95–106
  83. Rook AH, Lessin SR, Jaworsky C, et al.  Immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary cells. Arch. Dermatol. 1993;129:486–489
  84. Wood NL, Kitces EN, Blaylock WK. Depressed lymphokine activated killer cell activity in mycosis fungoides. Arch. Dermatol. 1990;126:907–913
  85. Wysocka M, Zaki MH, French LE, et al.  Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood. 2002;100:3287–3294
  86. Rook A, Wood GS, Yoo EK. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94:902–908
  87. Zaki MH, Wysocka M, Everetts SE, et al.  Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. J. Invest. Dermatol. 2002;118:366–371
  88. Housz-Oro SI, Bussel A, Flageul B, et al.  A prospective study on the evolution of the T-cell repertoire in patiens with Sézary syndrome treated by extracorporeal photopheresis. Blood. 2002;100:2168–2174
  89. Stevens SR, Baron ED, Masten S, Cooper KD. Circulating CD4+CD7− lymphocyte burden and rapidity of response. Arch. Dermatol. 2002;138:1347–1350
  90. Suchin KR, Cucchiara AJ, Gottleib SL, et al.  Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy. Arch. Dermatol. 2002;138:1054–1060
  91. Dolan ME, McRae BL, Ferries-Rowe E, et al.  O6-Alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin. Cancer Res. 1999;5:2059–2064
  92. Kyrtopoulos SA. O6-Alkylguanine-DNA alkyltransferase: influence on susceptibility to the genetic effects of alkylating agents. Toxicol. Lett. 1998;102:53–57
  93. el-Azhary RA, Gibson LE, Kurtin PJ, et al.  Lymphomatoid papulosis: a clinical and histopathological review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J. Am. Acad. Dermatol. 1994;30:210–218
  94. Wang HH, Myers T, Lach LJ, et al.  Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86:1240–1245
  95. LeBoit P. Lymphomatoid papulosis and cutaneous CD30+ lymphoma. Am. J. Dermatopathol. 1996;18:221–235
  96. Steinhoff M, Hummel M, Anagnostopoulos I, et al.  Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Neoplasia. 2002;100:578–584
  97. Kempf W, Levi E, Kutzner H, et al.  Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J. Cutan. Pathol. 2002;29:295–300
  98. Bekkenk MW, Greelen FA, van Voorst PC, et al.  Primary and secondary cutaneous CD30+ lymphoproliferative disorders with a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–3661
  99. Mori M, Manuelli C, Pimpinelli N, et al.  CD30–CD30 ligand interaction in primary cutaneous CD30+ T-cell lymphomas: a clue to the pathophysiology of clinical regression. Blood. 1999;94:3077–3083
  100. Natkunam Y, Warnke RA, Haghighi B, et al.  Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical, and molecular analysis of seven cases. J. Cutan. Pathol. 2000;27:392–399
  101. Schiemann WP, Pfeifer WM, Levi E, et al.  A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood. 1999;94:2854–2861
  102. Yagi H, Furukawa F, Takigawa M, et al.  Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-γ. J. Invest. Dermatol. 1996;107:827–832
  103. Vermeer MH, Tensen C, van der Stoop PM, et al.  Absence of Th2 cytokine messenger expression in CD30-negative primary cutaneous large T-cell lymphomas. Arch. Dermatol. 2001;137:901–905
  104. Friedmann D, Wechsler J, Delfau MH, et al.  Primary cutaneous pleomorphic small T-cell lymphoma. Arch. Dermatol. 1995;131:1009–1010
  105. von den Driesch P, Coors E. Localized cutaneous small to medium-sized pleomorphic T-cell lymphoma: a report of 3 cases stable for years. J. Am. Acad. Dermatol. 2002;46:531–535
  106. Wang CY, Su WP, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int. J. Dermatol. 1996;35:1–8
  107. Kumar S, Krenacs L, Medeiros J, Elenitoba-Johnson KS, et al.  Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum. Pathol. 1998;29:397–403
  108. McGinnis KS, Shapiro M, Junkins-Hopkins JM, et al.  Denileukin Diftitox for the treatment of panniculitic lymphoma. Arch. Dermatol. 2002;138:740–742
  109. LeBoit PE, Zackheim HS, White CR. Granulomatous variants of cutaneous T-cell lymphoma. The histopathology of granulomatous mycosis fungoides and granulomatous slack skin. Am. J. Surg. Pathol. 1988;12:83–95
  110. Rijaarsdam JU, Willemze R. Primary cutaneous B-cell lymphomas. Leuk. Lymphoma. 1994;14:213–218
  111. Giannotti B, Santucci M. Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity. Arch. Dermatol. 1993;129:353–355
  112. Wagner M, Rose VA, Linder R, Schulze HJ, Kruger GR. Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Clin. Infect. Dis. 1998;27:1299–12308
  113. Wechsler J, Willemze R, et al.  Differences in Epstein-Barr virus expression between primary and secondary cutaneous angiocentric lymphomas. Arch. Dermatol. 1998;134:479–484
  114. Viguier M, Rivet J, Agbalika F, et al.  B-cell lymphoma involving the skin associated with hepatitis C virus infection. Int. J. Dermatol. 2002;41:577–582
  115. Grange F, Wechsler J, Guillaume JC, et al.  Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J. Am. Acad. Dermatol. 2002;47:530–534
  116. Child FJ, Scarisbrick JJ, et al.  Inactivation of tumor suppressor genes p15INK4b and p16INK4a in primary cutaneous B-cell lymphoma. J. Invest. Dermatol. 2002;118:941–948
  117. Grange F, Bekkenk MW, Wechsler J, et al.  Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J. Clin. Oncol. 2001;19:3602–3610
  118. Geelen FA, Vermeer MH, Meijer CJ, et al.  Bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J. Clin. Oncol. 1998;16:2080–2085
  119. Mirza I, Macpherson N, Paproski S, et al.  Primary cutaneous cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J. Clin. Oncol. 2002;20:647–655
  120. Kerl H, Cerroni L. Primary B-cell lymphomas of the skin. Ann. Oncol. 1997;9:S29–S32
  121. Vermeer MH, Geelen FA, van Haselen CW, et al.  Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch. Dermatol. 1996;132:1304–1308
  122. Coiffier B, Lepage E, Brière J, et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242
  123. Maloney DG, Grillo-Lopez AJ, White CA, et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hogkin’s lymphoma. Blood. 1997;90:2188–2195
  124. Demirer T, Dail DH, Aboulafia DM. Four varied cases of intravascular lymphomatosis and a literature review. Cancer. 1994;73:1738–1745
  125. Perniciaro C, Winkelmann RK, Daoud MS, Su WPD. Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma: immunohistochemical, ultrastructural, and molecular genetics study. Am. J. Dermatopathol. 1995;17:242–248
  126. Cutaneous Lymphoma Task Force on plasma cell-rich cutaneous infiltrates, EORTC-workshop, Bilbao, 2001
  127. Chang YT, Wong CK. Primary cutaneous plasmacytomas. Clin. Exp. Dermatol. 1994;19:177–180
  128. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol. Oncol. Clin. North Am. 1995;9(5):1109–1116

PII: S0268-960X(03)00004-3

doi: 10.1016/S0268-960X(03)00004-3

Blood Reviews
Volume 17, Issue 3 , Pages 131-142 , September 2003

Article Tools

* Image Usage & Resolution